LBRX LB PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1691082 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-650.9%
TTM EPS YoY94.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-38.8%
ROA-36.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets7.9%
Debt / equity0.00x
Current ratio14.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $16.74M | $51.17M |
| SG&A expense | $13.66M | $13.66M |
| Pretax income | -$25.20M | -$63.10M |
| Income tax | $1,000 | $1,000 |
| Net income | -$25.20M | -$63.10M |
| EPS (basic) | -3.13 | -176.15 |
| EPS (diluted) | -3.13 | -176.15 |
| Weighted avg. shares (diluted) | 8.05M | 358,229 |
| Balance sheet | ||
| Cash & equivalents | $250.17M | $22.98M |
| Short-term investments | $45.04M | $5.02M |
| Current assets | $308.43M | $28.88M |
| PP&E, net | $1.58M | $1.86M |
| Total assets | $312.93M | $33.53M |
| Current liabilities | $7.44M | $8.11M |
| Total liabilities | $11.62M | $13.83M |
| Shareholders' equity | $301.31M | -$94.55M |
| Shares outstanding | 25.30M | 251,655 |
| Cash flow statement | ||
| Operating cash flow | -$35.21M | -$53.05M |
| Capital expenditure | $52,000 | $769,000 |
| Free cash flow | -$35.26M | -$53.82M |
| Investing cash flow | -$39.89M | $23.23M |
| Financing cash flow | $302.56M | $38.31M |
| Depreciation & amortization | $321,000 | $91,000 |
| Stock-based compensation | $4.19M | $3.09M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.